In this HealthTechQuity Spotlight, we spoke with Dr. Ameet Nathwani, CEO of Dewpoint Therapeutics, whose career spans clinical medicine, Big Pharma leadership, and now biotech innovation. His mission? Bridging the gap between cutting-edge science and real-world impact especially in underserved communities.
Dr. Nathwani began his career in hospital medicine before moving into executive roles in global pharma, where he saw first hand how access to care and outcomes varied dramatically around the world. That experience led him to a core question: How do we democratize science so that innovation benefits more people, not just a few?
At Dewpoint, he’s tackling that challenge head-on by using AI and automation to streamline drug discovery aiming to deliver powerful therapies that are also affordable and scalable. Rather than relying solely on high-cost breakthroughs like gene therapy, Dewpoint’s model is to build smart, efficient solutions that reach wider populations.
One reason Dr. Nathwani left Big Pharma for biotech? Speed and agility. “You just can’t move fast enough in big companies,” he explains. “Biotech lets us pivot, experiment, and combine disciplines in ways that really drive progress.”
His leadership philosophy is rooted in curiosity and collaboration. A key lesson from a former mentor, the late Dr. Tachi Yamada, shaped his thinking: “Don’t fear not knowing, get excited about discovering.” That mindset fuels his approach to building diverse, innovative teams that aren't afraid to challenge assumptions.
Discussing the biotech industry at large, Dr. Nathwani outlined four key pillars that must work in sync: academic research, capital markets, regulatory systems, and pharma partnerships. All are in flow, and he sees this as an inflection point an “evolutionary moment” where nimble, purpose driven companies can thrive while outdated models fade.
On health equity, he doesn’t see a single company solving everything, but applauds efforts like Omada Health (AI-driven chronic care) and KaNDy (focused on women’s health). Dewpoint’s own role is to target high unmet needs globally, using cost-effective tech that ensures accessibility from day one.
Looking ahead, he envisions a deeply connected biotech ecosystem where AI, biology, and big data converge, and collaboration becomes the default across academia, start-up's, and regulators. “It won’t be siloed anymore,” he says. “It’ll be networked innovation.”
He left us with a powerful question for future biotech leaders: “If you’re building a company at the intersection of AI and biology, how should we rethink leadership, talent, and capital for this new era?”
It’s a question that signals where the industry is headed and what it will take to build biotech that works for everyone.